A Novel Biologic Therapy for Perennial Allergic Rhinitis

Summary

This is a randomized, parallel-group, double-blind, phase 2, single center, proof-of-concept study which will evaluate the effect of a preparation of FDA approved allergens (PMA) used as a sub-cutaneously administered immunotherapy for the management of allergic rhinitis (perennial and seasonal).

Timeline

Start

2016-12-19

Primary completion

2018-06

Completion

2018-11-01

Drugs

Indications